Drug Profile
Research programme: herpes simplex virus vaccine - PaxVax/University of California at San Diego
Alternative Names: Genital herpes vaccine - PaxVax/UCSD; Herpes simplex combination vaccineLatest Information Update: 11 Oct 2018
Price :
$50
*
At a glance
- Originator PaxVax; University of California, San Diego
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
- 28 Jul 2018 No recent reports of development identified for research development in Herpes-simplex-virus-infections(Prevention) in USA (Parenteral)
- 10 Jun 2014 Early research in Herpes simplex virus infections in USA (Parenteral)